Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model

Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model

Bladder cancer is an increasingly prevalent global disease that continues to cause morbidity and mortality despite recent advances in treatment. Immune checkpoint inhibitors (ICI) and fibroblast growth factor receptor (FGFR)-targeted therapeutics have had modest success in bladder cancer when used a...

Full description

Bibliographic Details
Main Authors: Daniel R. Bergman, Yixuan Wang, Erica Trujillo, Anthony A. Fernald, Lie Li, Alexander T. Pearson, Randy F. Sweis, Trachette L. Jackson
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Immunology
Subjects:
agent-based model
bladder cancer
FGFR3
immune checkpoint inhibition
CD8+ T cells
Fas/Fas ligand
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1358019/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1358019/full

Similar Items